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Single step syntheses of (1 S)-aryl-
tetrahydroisoquinolines by norcoclaurine synthases
Rebecca Roddan 1,2, Altin Sula 1, Daniel Méndez-Sánchez 2, Fabiana Subrizi2, Benjamin R. Lichman 3,6,
Joseph Broomfield 2, Michael Richter4, Jennifer N. Andexer5, John M. Ward 3✉, Nicholas H. Keep 1✉ &
Helen C. Hailes 2✉
The 1-aryl-tetrahydroisoquinoline (1-aryl-THIQ) moiety is found in many biologically active
molecules. Single enantiomer chemical syntheses are challenging and although some bio-
catalytic routes have been reported, the substrate scope is limited to certain structural motifs.
The enzyme norcoclaurine synthase (NCS), involved in plant alkaloid biosynthesis, has been
shown to perform stereoselective Pictet–Spengler reactions between dopamine and several
carbonyl substrates. Here, benzaldehydes are explored as substrates and found to be
accepted by both wild-type and mutant constructs of NCS. In particular, the variant M97V
gives a range of (1 S)-aryl-THIQs in high yields (48–99%) and e.e.s (79–95%). A co-
crystallised structure of the M97V variant with an active site reaction intermediate analogue
is also obtained with the ligand in a pre-cyclisation conformation, consistent with (1 S)-THIQs
formation. Selected THIQs are then used with catechol O-methyltransferases with excep-
tional regioselectivity. This work demonstrates valuable biocatalytic approaches to a range of
(1 S)-THIQs.
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The tetrahydroisoquinoline (THIQ) moiety is present inmany biologically activeQ1 molecules and so is a desirablesynthetic target for pharmaceutical research. Generating
single enantiomer and single regioisomer THIQ products is
synthetically challenging. The 1-aryl THIQ moiety is found in
many synthetic biologically active small molecules (examples
shown in Fig. 1a), which have a variety of medicinal benefits,
including anti-tumour1,2, anti-HIV3 and contraceptive4 activities
and natural products have also been isolated (Fig. 1b). Solifenacin
succinate is a widely prescribed muscarinic receptor antagonist,
used for the treatment of an overactive bladder with ~3 million
US prescriptions per year5.Q2 Q3456
Routes to racemic 1-aryl-THIQs areQ7 currently via
Pictet–Spengler reactions (acid or phosphate catalysed)6,7 or via a
three-step synthesis, involving amide formation, a
Bischler–Napieralski cyclisation to give the imine, followed by
reduction to give the final THIQ scaffold8. However, these
approaches are limited by poor reactivity and stereoselectivity
(Pictet–Spengler reactions) or the use of forcing conditions (via
the Bischler–Napieralski reaction).
Enantioselective syntheses of small molecules are meaningful
because each enantiomer can possess different biological activ-
ities. Synthetic routes involve a chiral inductor9 or most com-
monly, a stereoselective reduction of the imine using an inorganic
catalyst (often iridium-based)10–12. These catalysts can, however
have narrow substrate scopes. In another synthetic route devel-
oped by Chen et al.12, the asymmetric hydrogenation of the
heterocyclic ring of a variety of isoquinolines was performed
using a chiral iridium catalyst, giving a range of (1 R)-THIQ
products in high yields (>80%) and high enantiomeric excesses (e.
e.s.; 90–99%). However, hydrogenation must be performed under
high pressure (ca. 80 bar), the isoquinolines must be first pre-
pared synthetically, and there are sustainability issues associated
with the use of iridium13–15.
Some enzymatic routes have been developed to generate single
enantiomer 1-aryl-THIQs. Routes using imine reductases
(IREDs), from the corresponding dihydroisoquinoline, have
involved the directed evolution of artificial metalloenzymes based
upon biotin–streptavidin binding16 or the screening of large
catalogues of IREDs17,18. However, there is a synthetic require-
ment to generate the starting material and harsh reaction con-
ditions are involved. Another route to these compounds involves
the use of an enantiospecific monoamine oxidase (MAO),
developed using directed evolution methods19. The MAO selec-
tively oxidises a single enantiomer of a racemic THIQ to give the
imine, which is reduced in situ, resulting in the accumulation of
the opposing single enantiomer of amine to the one that the
MAO oxidises. Single enantiomers of a range 1-aryl-THIQs can
be generated using these methods in high yields and e.e.s.;
however, starting materials must be synthesised chemically and
oxidatively sensitive groups (such as hydroxyls) are not tolerated
on the bicyclic ring system, although this moiety is found in
biologically active compounds (Fig. 1a).
The majority of examples of naturally occurring THIQs are
benzylic at the C-1 position, generated in the NCS-mediated
pathway to benzylisoquinoline alkaloids. A variety of enantiopure
1-aryl-THIQs, known as the cryptostylines have been isolated
from two species of orchid in the 1970s (as shown in Fig. 1b).
Interestingly, in Cryptostylis erythroglossa, solely the R-enantio-
mer of product was isolated and in Cryptostylis fulva, only the S-
enantiomer was found (Fig. 1b)20,21. The stereochemistry of the
isolated products was determined by x-ray crystallography22.
Some isotope feeding studies were performed and determined
that the amine required was dopamine, generated from tyrosine
or phenylalanine in an analogous pathway to the biosynthetic
routes in BIA-producing plants. The biosynthetic origin of the
phenyl group at C-1 is unknown21. Due to the apparent isolation
of single isomer products, it is likely that the biosynthesis involves
an epimerase or Pictet–Spenglerase.
Work recently published by our group23, showed that despite
previous reports, α-methyl-substituted aldehydes are well-
tolerated as substrates for TfNCS. When a racemic aldehyde
was used as the carbonyl substrate, a kinetic resolution of the
aldehyde was performed by the wild-type (WT) enzyme, giving
THIQ products with (1 S,1′ R) stereochemistry in high diaster-
eomeric ratios (d.r.s.; up to 96:4). Two active site mutants, L76V
and M97V were shown to improve d.r.s. (up to 98:2) and con-
versions in products (up to >99%), respectively23. TfNCS has also
been shown to accept a variety of bulky ketones as substrates, to
generate 1,1-disubstituted THIQs24. Therefore, it is not implau-
sible that benzaldehydes may also be accepted as substrates.
Previous reports have shown that benzaldehyde derivatives
were not well-tolerated as substrates by NCSs. Screening showed
that only trace amounts of product were generated using ben-
zaldehyde or 3-hydroxybenzaldehyde as substrates using WT-
TfNCS or CjNCS2 (isolated from Coptis japonica)25,26. In both
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Fig. 1 Pharmaceutically relevant 1-aryl-THIQs, naturally occurring 1-aryl-
THIQs and a proposed route to these compounds using TfNCS (NCS
isolated from Thalictrum flavum). A range of a pharmaceutically relevant
1-aryl-THIQs and b the Cryptostylines, a variety of naturally occurring
enantiopure 1-aryl-THIQs isolated from C. fulva. The analogous levorotatory
compounds were isolated from C. erythroglossa20,22. c The generation of a
variety of (1 S)-aryl THIQ products in a single, regioselective and
enantioselective step, using TfNCS as a reaction catalyst (WT or single-
point variant).
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cases, enzymatic assays were performed with low substrate
loading (10 μM–1 mM) and some of the product could have
possibly been generated by non-enzymatic reactions. Subsequent
studies have reported high Kd values for both amine and aldehyde
substrates, indicating that high substrate loading is necessary for
increased conversions27. Indeed, attempts to generate unnatural
THIQ products using alpha-substituted amino acids (L-valine
and L-isoleucine) in vivo, using a yeast-based platform have been
unsuccessful, probably as high substrate loading is challenging to
achieve in these systems28. In this work, we hypothesise that by
modification of the reaction conditions, such as enzyme or sub-
strate loading, and using WT and variants of TfNCS together with
benzaldehydes, the portfolio of asymmetric THIQs that can be
synthesised via Pictet–Spenglerases can be significantly expanded.
This can also lead to the first single-step syntheses of a range of
(1 S)-1-aryl-THIQs which are challenging to synthesise chemi-
cally due to the oxidatively sensitive catechol (Fig. 1c).
Results and discussion
Expanding the NCS substrate scope. Previous work in our group
has shown that α-methyl-substituted aldehydes are accepted as
NCS substrates, despite earlier reports indicating little or no
acceptance25,29. From this, initial test screens were performed
using WT-TfNCS and variants (L76V, M97F and M97V), with 1,
and the substrates 2-methyl-2-pentenal (2a) and 2-ethylbutanal
(2b), where low conversions were previously observed with the
WT enzyme (Fig. 2)23. These were selected as representative of
larger disubstituted groups at the alpha-position and an sp2-car-
bon as is the case in benzaldehydes. There is interest in accessing
the THIQ product (3b) as the racemic compound has been
shown to act as a bronchodilator30,31.
For enzymatic reactions between dopamine (1) and (2a),
conversions were similar when using the mutant and the WT
constructs. Based on a co-crystallised structure of NCS gained
with an α-methyl-substituted reaction mimic (PDB: 6RP3), the
aldehyde side chain (i.e., here -C(CH3)(= CHC2H5) is likely to be
proximal to the L76V region in the active site23. However, due to
the lack of rotational freedom of this, a small increase in space
may not be sufficient to improve conversions and conjugation of
the alkene with the aldehyde, resulting in poor activation of the
aldehyde. For conversions with 2-ethylbutanal (2b) as the
substrate, a fourfold improvement was observed with M97V
(and also interestingly by M97F), further highlighting its
applicability with α-substituted aldehydes as substrates. These
initial screens indicated that unsaturated aldehydes and more
sterically challenging α-disubstituted aldehydes could be accepted
by NCS variants.
Acceptance of benzaldehyde and derivatives by NCS. In pre-
vious screens, when dopamine and benzaldehyde were used with
TfNCS, products were not detected or trace conversions were
observed, possibly due to the lower enzyme or substrate loading
used25. As demonstrated in previous reports, high substrate
loading is well-tolerated by NCS and is indeed required to gain
high conversions of the substrate (or high yields of product)23,24.
The Kd value of dopamine was determined by NMR titration
experiments and found to be 5 mM, thus indicating very weak
substrate binding27. With this in mind, assays performed in this
study used increased substrate loading; 10 mM amine and 20 mM
aldehyde. An excess of aldehyde was used as benzaldehydes can
be easily oxidised32. Assays were performed using benzaldehyde
and a variety of analogues with dopamine (1) as the amine
substrate. Conversions using WT-TfNCS and the mutants L76V,
M97F and M97V are given in Fig. 3. Reactions were performed
for 3 h to minimise the contribution of the background
Pictet–Spengler reaction between the two substrates, as the
aldehyde is highly activated33,34. Racemic standards for chiral
HPLC analyses were prepared using a phosphate-mediated
Pictet–Spengler reaction (Supplementary Fig. 7 and Supplemen-
tary Methods).
Remarkably, all the benzaldehydes screened, possessing both
electron-donating and electron-withdrawing groups (4a–k), were
accepted as substrates by all NCSs, including WT-TfNCS, despite
previous reports of no or trace conversions (Fig. 3)25. Indeed, on
performing the reaction to give 5b under the conditions described
by O’Connor et al. (in their supplementary data) only trace
amounts of 5b were formed (Supplementary Fig. 9). Modification
of these conditions, highlighted that both higher enzyme and
substrate concentrations enhanced product formation.
High enantiopurity was observed with 4a (>99% for all TfNCS
variants). Conversions with WT-NCS and L76V with aldehydes
4a–k were similar and conversions with both substitutions at
residue 97 resulted in improved yields. This is particularly
interesting with the M97F variant as due to the bulky phenyl
group, there is less space in this region of the active site23. In
addition, for reactions with ketones as substrates, mutations at the
M97 position (to phenylalanine, leucine or valine) resulted in
poorer yields compared with WT-TfNCS. Previous NMR and
molecular dynamics studies of WT-TfNCS enzyme, indicated it to
be highly dynamic during the catalytic process with substrate
binding, resulting in large conformational changes across the
entire protein23,27. The increased conversions and e.e.s. in
products from reactions with M97F and M97V could therefore
be due to an effect whereby when faster binding of the substrates
occurs (by increasing hydrophobicity or active site space,
respectively) and turnover is faster, so the background
Pictet–Spengler reaction is less efficient and product enantiopur-
ity is improved.
The effects of electron-donating (4c–e) and electron-
withdrawing substituents (4f–k) on the aldehyde aromatic ring
were explored by performing reactions with ortho-, meta- and
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Fig. 2 HPLC conversions (determined against product standards) of
reactions between dopamine and 2-methyl-2-pentenal or 2-ethylbutanal.
Reaction between dopamine (1) and a 2-methyl-2-pentenal (2a) to give
(3a) or b 2-ethylbutanal (2b) to give 3b. TfNCSs were used as reaction
catalysts at 0.2 mgmL−1 concentration. Reactions were performed in
triplicate and standard deviations reported.
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para-substituted analogues. For reactions with the substituted
aldehydes (4a and 4c–k), e.e.s. in the product were decreased
compared with benzaldehyde (4b), despite often low or no
observed background reactions. This suggested that the lower
stereoselectivities were due to imine intermediate positioning in
the active site. This was most notably observed with the more
activated aldehydes, the ortho-halogenated benzaldehydes (4f and
4i). The fluorinated benzaldehydes (4f–h), which are of a similar
size to benzaldehyde, were well-accepted as substrates. Para-
substitutions on the aryl ring were generally less well-tolerated,
potentially due to steric hinderance in the active site, particularly
with methyl- and chloro-substituted benzaldehydes (4e and 4k,
respectively). Using these reaction conditions, enzymatic reac-
tions towards 5a–k were performed on a biocatalytic preparative
scale (10 mL scale), with products readily isolated and char-
acterised (Supplementary Methods).
With a view to further extending the benzaldehyde substrate
scope, further activated halogenated and a heterocyclic derivative
(4l–o, Fig. 3a) were tested, however, all were poorly accepted.
Para-substitution has already been shown to be poorly tolerated
(4e, h and k, Fig. 3b) and performing reactions with para-
hydroxylated (4 m) and para-brominated (4n) aldehydes resulted
in trace conversions, probably due to increased steric hindrance
in the active site. The meta-hydroxylated aldehyde (4 l) was also
poorly accepted, likely due to carbonyl deactivation and steric
effects. A high background reaction was observed with 2-
pyridinecarboxaldehyde (4o) as a substrate because the aldehyde
is highly activated due to electron-withdrawing effects.
Optimisation of reaction conditions. It was hoped that reaction
optimisation using the most productive variant M97V could lead
to higher conversions and e.e.s in the products. Timepoint assays
Fig. 3 Initial TfNCS-catalysed reactions between dopamine and aldehydes 4a–o. a Reactions performed between dopamine (1) and aldehydes (4a–k).
Reactions with aldehydes 4l–o were performed using 0.5 mgmL−1 final concentration of Δ29TfNCS-M97V. b Conversions of reactions between dopamine
(1) and benzaldehyde derivatives (4a–k). WT-TfNCS or active site mutants of TfNCS were used as the reaction catalyst with 0.2 mgmL−1 enzyme.
Samples were prepared by workup method 1, conversions were determined by monitoring product formation against standards (Supplementary Figs. 24–
26 and Supplementary Methods) by analytical achiral HPLC (method 1). Product enantiomeric purities are given by indicating the amounts of R- and S-
product generated and were determined by chiral HPLC analysis. Reactions were performed in triplicate and standard deviations reported.
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were therefore performed for the reactions between dopamine (1)
and a representative substrate meta-methylbenzaldehyde (4d)
(Supplementary Fig. 8), using varying concentrations of M97V as
the reaction catalyst with the reactions halted at various time-
points. For an NCS-mediated reaction with an enzyme con-
centration of 0.2 mg mL−1 and a reaction time of 3 h (Fig. 3b), the
product (5d) was obtained in poor enantiopurity (67% e.e.) and
low yield (31%). Using higher enzyme concentrations (0.5 mgmL
−1), a high racemic background reaction was again observed (15%
conversion after 24 h). However, the amount of R-product
formed was higher than would be expected based upon the
reactions in the absence of enzyme, suggesting that this is an
enzyme-mediated reaction, but high concentrations of enzyme
are also required for fast turnover of the substrates to give high e.
e.s. For all reactions with 4d, with 0.2 mgmL−1 of enzyme e.e.s of
74–78% were observed, whereas for 0.5 mgmL−1 enzyme, e.e.s of
84–85% were observed at 2–6 h, increasing to an e.e. of 87% at
24 h, combined with very high conversion levels (94%). These
reaction conditions were then used with the other aldehydes
(4a–k) (M97V-Δ29TfNCS 0.5 mgmL−1, 24 h) and the conver-
sions, with the amounts of R and S products generated, are given
in Fig. 1a, b.
Complete conversions were observed for reactions to give 5a
and 5b with both products formed in excellent enantiopurities
(97% and >99%, respectively, Fig. 4a). These conditions also
significantly improved both the conversions and enantiopurity of
the products with methylated benzaldehyde derivatives (4c–e).
Conversions of 76% and 90% were observed for the ortho- (4c)
and meta- (4d) substituted compounds, respectively, in >90% e.e.
Lower enantiopurity and conversions were again observed with
the para-substituted analogue (4e), (68% e.e. and 45% yield).
Despite the observation of a high racemic background reaction
for NCS-catalysed reactions involving fluorinated benzaldehyde
derivatives, reasonable e.e.s in the products were obtained
(68–88%). Higher background reactions were observed for
reactions with the chlorinated benzaldehydes (4i-k). Interestingly,
a similar trend was observed with the halogenated analogues;
lower background reactions were observed with the para <meta
< ortho. Presumably, this is due to a combination of steric factors
and activation of the carbonyl group. Despite this, the para-
chlorinated product (5k) was generated in reasonable yield (41%),
and increased enantiopurity (75% vs. 21% e.e., Fig. 4b vs. Fig. 3).
Gaining high e.e.s. in the products for reactions with
halogenated benzaldehydes (5f–k) still proved challenging. It
was hypothesised that this was due to a combination of a high
background reaction (as the aldehydes are highly activated) and it
was suspected that this could be due to increased lability of the C-
1 proton, due to the presence of electron-withdrawing halogen
atoms on the aryl ring. In an attempt to minimise in situ
racemisation at this position, reactions were performed at a lower
pH (6 vs. 7.5). Conversions and enantiomeric ratios of the
resulting products (5f–k) are given in Fig. 4c.
Remarkably, improved yields and e.e.s. were observed in all
cases. In particular, with the ortho-chlorinated product (5i), at pH
7.5, the yield and e.e. observed were 40% and 19%, respectively,
whereas at a lower pH, both were improved to 57% and 79%. This
was in part due to the minimal background reaction observed,
which was unexpected, considering that the Pictet–Spengler
reaction is catalysed by acidic conditions. Previous reports of
TfNCS-catalysed reactions are typically performed at near neutral
pH (7–7.5)29,35,36, so it is interesting that performing reactions at
pH 6 improves both the enantiopurity and conversions with these
substrates. It is possible that the catecholic side reactions are
reduced at this pH. It is however clear that optimising reaction
conditions is worthwhile for each substrate type.
Determination of the absolute stereochemistry of products. To
confirm the stereochemistry at the C-1 position, the product 5b
was O-methylated as chiral HPLC and optical rotation data has
been reported for this analogue37. THIQ 5b was first N-Boc
protected (Supplementary Fig. 29). Deprotonation of the catechol
is required for methylation to occur; however, the C-1 proton of
the N-Boc protected THIQ is labile due to the neighbouring,
electron-withdrawing Boc group. Attempts to perform this step
using potassium carbonate as the base were unsuccessful, with
racemisation observed (Supplementary Figs. 21 and 22). There-
fore, the reaction was repeated, using a bulkier base, caesium
carbonate. An e.e of 20% was observed in the resultant product,
with the major peak corresponding to the (1 S)-isomer (Supple-
mentary Figs. 21 and 22), confirming that the major enantiomer
in the 1-aryl-THIQs generated by NCSs was (1 S). Full synthetic
procedures given in the Supplementary Methods.
Co-crystallised structure of M97V-TfNCS with a mimic. To
gain further insight into the NCS mechanistic process, a co-
crystallised structure of the most promising single-point variant,
M97V, with a non-productive reaction intermediate bound in the
active site was obtained. This approach has been successful for
O O OO O O O O O O O
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O O O O O O
F
F
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Fig. 4 Conversions (determined against product standards) and enantiomeric excesses of products generated by a M97V-Δ29TfNCS-catalysed
reaction between dopamine and a variety of aldehyde derivatives. Reactions were performed using 0.5 mgmL−1 final concentration of enzyme for 24 h. a
Reactions between dopamine (1) and 4a-e at pH 7.5. b Reactions between dopamine (1) and 4f–k at pH 7.5. c Reactions between dopamine (1) and 4f–k at
pH 6. Reactions were performed in triplicate and the error bars given are the standard deviations.
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gaining mechanistic insights into the WT enzyme23,38 and has
recently been used to show that when altering the aldehyde
substrate of another Pictet–Spenglerase, strictosidine synthase,
inverted substrate binding occurred compared with when using
the natural substrates39. The non-productive secondary amine
mimic (6) of the iminium ion intermediate of the reaction
between 1 and 4b was synthesised (Supplementary Fig. 30 and
Supplementary Methods), and a truncated construct of M97V-
TfNCS generated, M97V-Δ33TfNCS, omitting residues (1–33 and
196–210; Supplementary Figs. 1–3 and Supplementary Methods)
in the signal peptides at both termini, as with previous stu-
dies23,38. A co-crystallised structure was gained of M97V-
Δ33TfNCS with 6 bound in the active site (Fig. 5) at 2.3 Å with a
single copy in the asymmetric unit (PDB: 6Z82; Supplementary
Table 1, Supplementary Fig. 23, and Supplementary Methods).
The ligand orientation was consistent with the ‘dopamine-first
mechanism’ with mechanistically relevant hydrogen-bonding
interactions observed between the catechol moiety of 6 and
K122, and the secondary amine of 6 and E110. The ligand was
also observed in a pre-cyclisation conformation, which interest-
ingly was consistent with the stereochemical outcome of the NCS
reaction with benzaldehydes as substrates40. The analogous
iminium ion to 6 would be in a trans-conformation, oriented
for Re-face attack by the pi-system, thus resulting in the (S)-
quinone, followed by deprotonation to give a (S)-THIQ. This
structure is also unique as it is the first crystallographic study of a
TfNCS variant and shows that it is highly conserved, compared to
the WT structure. Residue V97 sits close to the alkyl region of the
dopamine end of the putative iminium carbon of the mimic. The
mutation from methionine to valine decreases both flexibility,
and steric bulk at this position, so the reasons for increased
conversions may be due to faster substrate binding. It is however
unknown how conversions are improved with the M97F variant
compared with the WT enzyme, and possible that there may be
pi-stacking interactions with the benzaldehyde phenyl ring at
some point in the mechanistic process, thus aiding substrate
turnover.
Increasing molecular complexity using O-methyltransferases.
A variety of meta-methoxylated, N-acylated 1,2,3,4-THIQs
(Fig. 6) are under patent for preventing or treating numerous
degenerative or inflammatory diseases, by inhibiting the pro-
duction of inflammatory substances by activated microglial
cells41. Performing the regioselective meta-methylation of a
catechol is challenging chemically, as there is a lack of regiose-
lective control and synthetic routes, therefore, require the use of a
precursor with the correct methylation pattern and/or employ a
multi-step, protecting group strategy.
There are several research efforts into the discovery and
isolation of regioselective methyltransferase enzymes, to avoid the
Fig. 5 Crystallographic investigations of M97V-TfNCS. a Rationale of (6) design, a non-productive analogue of the iminium ion intermediate of the NCS-
mediated reaction between 1 and 4b, to give 5b. b–d Location of 6 bound in the active site of M97V-Δ33TfNCS (PDB: 6Z82), with the mutation M97V
given in blue.
NR
MeO
HO
R= Me, Et, Pr, Bu, CH2Ph, COCH3
NR
MeO
HO
Fig. 6 Examples of some patented meta-methoxylated, N-acylated
1,2,3,4-THIQs. The compounds shown have been patented for the
treatment of a range of neurodegenerative diseases.
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challenges of synthetic, regioselective methylations42. Regioselec-
tive methylation reactions are also particularly useful for drug
discovery purposes due to ‘the magic methyl effect’, whereby the
substitution of H to CH3 can increase the potency of a drug
molecule by up to 100-fold. In 2011, it was noted that methyl
groups are found in >67% of the year’s top selling drugs43.
Beyond the advantage of controlled regioselectivity, biocatalytic
reactions involving methyltransferases are more environmentally
benign than traditional, chemical alternatives as they avoid the
use of carcinogenic alkylating agents (for example, methyl iodide)
as the methyl donor. However, the major barrier to the
widespread applicability of these enzymes in preparative-scale
syntheses is the narrow substrate scope of many of the enzymes
discovered and the requirement for stoichiometric quantities of
the methyl donor, (S)-adenosyl-L-methionine (SAM). SAM is
expensive and unstable, so reactions are not economically viable
on a preparative scale. Recent efforts to overcome this have
involved the use of an enzymatic co-factor generation system.
Instead of using SAM directly, adenosine triphosphate (ATP) and
L-methionine are added to the reaction with two enzymes so that
SAM is formed in situ using a methionine adenosyl transferase
(MAT, E.C.2.5.1.6), and the product (S)-adenosyl-L-homocys-
teine (SAH), is broken down by methylthioadenosine/SAH
nucleosidase (MTAN, E.C.3.2.2.9) to prevent inhibition of the
methyltransferase reaction44.
A range of regioselective catechol O-methyltransferases have
been reported in the literature to accept various catecholamines as
substrates, but the substrate scope has not yet been extended to
THIQs. Two catechol O-methyltransferases were selected;
RnCOMT (isolated from Rattus norvegicus) andMxSafC (isolated
from Myxococcus xanthus)45. For reactions involving RnCOMT,
methylation is most commonly observed on the meta-hydroxyl.
The known substrate scope includes a variety of catecholamines
(dopamine, dihydrocaffeic acid and 3,4-dihydroxybenzoic acid)
45,46. The enzyme is often not completely regioselective, and some
para-methylation can be observed45. On the other side,MxSafC is
reported to have complementary regioselectivity, with methyla-
tion favoured at the para-position with L-dopa, dopamine and
caffeic acid, although a preference for the meta-position is
observed with 3,4-dihydroxybenzoic acid47.
Methylation reactions were performed using analogous condi-
tions to those detailed by Siegrist and co-workers44, except that
unpurified preparation of the substrate and purified MAT
enzyme from Escherichia coli (Supplementary Figs. 5 and 6, and
Supplementary Methods) was used due to the increased activities
with L-methionine, rather than TkMAT (from Thermococcus
kodakarensis), as previously reported44. The two O-methyltrans-
ferases (RnCOMT and MxSafC; Supplementary Fig. 4 and
Supplementary Methods) were tested with two (1 S)-1-substituted
THIQ products (5a and 5b) generated from the NCS reaction.
Achiral HPLC traces of the reactions performed are shown in
Fig. 7. The analytical HPLC trace of the product of the NCS
reaction is also shown for comparison.
The regioselectivities of the resultant products were determined
based on 2D-NMR spectroscopic data of the purified products
and compared to the observed RP-HPLC traces. For methylations
involving RnCOMT, a ratio of 87:13 of C6:C7-OMe-7b was
observed by 1H-NMR when 5b was used as the substrate (Fig. 7b)
along with complete consumption of the starting material.
Interestingly, altering the phenyl ring to a cyclohexyl ring, using
5a as the substrate, gave remarkable regioselectivity, with only
C6-OMe-7b observed (Fig. 7a). Perhaps the presence of a bulkier,
more flexible ring at the C-1 position means that the catechol is
only capable of binding to the magnesium-bound ion in the
methyltransferase in a single orientation. Exceptional
regioselectivities were also observed for reactions involving
MxSafC, with only meta-methylation observed in products 7a
and 7b (Fig. 7), again giving C6-OMe-7a and C6-OMe-7b. This is
interesting as in previous reports, the enzyme is predominantly
shown to be regioselective towards the para-position, when
dopamine (1) and dihydrocaffeic acid are used as substrates.
However, when 3,4-dihydrobenzoic acid was used as a substrate,
the enzyme was observed to methylate predominantly at the
meta-position45. The regioselectivity is clearly highly dependent
on the catechol side chain. The enantioselectivities towards 5a
and 5b with both methyltransferases were determined based upon
RP-HPLC and chiral HPLC analyses of reaction mixtures,
compared to starting materials and product standards (Supple-
mentary Methods, and Supplementary Figs. 27 and 28).
RnCOMT was found to not be enantioselective, with complete
consumption of rac-5a and rac-5b observed in methylation
reactions. However MxSafC was found to be selective towards
both (S)-5a and (S)-5b. This provides valuable insights into future
applications of such methyltransferases.
Preparative-scale reactions were performed using the most
promising methyltransferase, MxSafC. Conversions, when using
5 mM substrate in 20 mL reaction volume, were found to be 33%
(7a) and 46% (7b), respectively, as determined by RP-HPLC
analysis of the two products compared with calibration curves of
purified product standards (achiral analytical HPLC method 2,
Supplementary Fig. 26, and Supplementary Methods).
Conclusions
In this work, a variety of benzaldehydes were shown to be readily
accepted in TfNCS-mediated reactions with both WT and single-
point variant enzymes. Previous reactions were performed with
lower enzyme and substrate concentrations: here, as well as
increased enzyme concentrations, higher substrate loadings were
successfully used (10–20 mM) due to the low Kd of dopamine
binding with TfNCS. The active site mutant, M97V proved par-
ticularly promising and was capable of generating a variety of (1
S)-aryl THIQ derivatives in high yields and high e.e.s. This route
is advantageous as the chiral THIQ scaffold can be generated in a
single step under benign conditions, avoiding the use of high
temperatures, high pressures and toxic reagents. Oxidatively
sensitive hydroxyl groups were also tolerated on the THIQ
moiety, which is valuable as analogous compounds are biologi-
cally active. In addition, although high background reactions were
observed with a variety of halogenated (fluorinated and chlori-
nated) benzaldehyde derivatives as substrates, when using high
enzyme loading and lowering the reaction pH to 6, the con-
tribution of the spontaneous background reaction decreased,
enzyme activity improved and this enhanced the enantiopurity of
the resultant THIQ products. The mutant M97V proved to be
superior in generating a range of (1 S)-aryl-THIQs in high yields
and e.e.s. A co-crystallised structure of this productive mutant
(M97V) was gained with a non-productive reaction intermediate
analogue (of the reaction between dopamine and benzaldehyde)
bound in the active site. The ligand was found to be in a pre-
cyclisation conformation, consistent with the generation of pro-
ducts with (1 S)-stereochemistry. In future studies, further
mutagenesis at this position could be explored, possibly to even
smaller sidechains on the amino acid.
The products of NCS reactions between dopamine and ben-
zaldehyde or cyclohexanecarboxaldehyde were also accepted, as
substrates by O-methyltransferases. Regioselective methylation of
the meta-hydroxyl was achieved using SafC from M. xanthus,
which is unusual as with other catecholamines, the methylation is
predominantly selective towards the para-hydroxyl. Performing
regioselective methylation reactions is challenging chemically and
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the products generated here are pharmaceutically relevant. The
expansion of the portfolio of regioselective methyltransferases
available will likely lead to increased conversions to give both
meta- and para-methoxy products, thus generating useful ana-
logues for drug discovery purposes.
Methods
Cloning and enzyme sequences. Plasmid details for M97V, L76V, M97F and WT
Δ29TfNCS have been previously reported by Lichman et al.24. Plasmid details for
the methyltransferase enzymes, RnCOMT, MxSafC, EcMAT and EcMTAN (Sup-
plementary Methods) have been previously reported by Siegrist et al.45. For
Δ33TfNCS, a truncated (residues 33–196 only), codon-optimised construct of the
WT-TfNCS gene with a single-point mutation, M97V (M97V-Δ33TfNCS) with an
N-terminal hexahistidine tag and Tobacco Etch Virus (TEV) protease cleavage site
(N-6His-TEV-M97V-Δ33TfNCS) was synthesised and cloned into BL21(DE3).
UniProt codes are: TfNCS (Q67A25), RnCOMT (P22734), MxSafC (Q50859),
EcMAT (D1LDF1) and EcMTAN (A7ZHQ1). Protein sequences and full plasmid
details are given in the Supplementary Methods.
Protein expression. All plasmids were transformed into BL21(DE3) E. coli. A total
of 100 mL LB medium was inoculated with a single colony and grown at 37 °C for
18 h. A total of 500 mL LB media was inoculated with 1% v/v of overnight culture
and grown at 37 °C for 2 h shaking in flasks. Isopropylthiogalactoside (for all NCSs,
0.5 mM final concentration was used and for RnCOMT, MxSafC, EcMAT and
EcMTAN 0.2 mM final concentration was used) was added and the culture was
incubated for 18 h at 25 °C (for all gene expressions except MxSafC, where incu-
bation was performed at 16 °C for 36 h). Cell pellets were isolated by centrifugation
and stored at −20 °C until further purification or lysis for enzymatic reactions.
Lysate preparation. To prepare RnCOMT lysate for enzymatic reactions, the
pellet was resuspended in buffer (4% v/v of final culture volume, 50 mM HEPES,
pH 7.5) and cells were lysed by sonication (10 s ON, 10 s OFF, 10×). The resulting
suspension was centrifuged (10 min, 6000 × g, 4 °C) and the supernatant used
directly for enzymatic reactions or stored at −20 °C.
Protein purification. For purification of 6His-TEV-M97V-Δ33TfNCS and WT,
M97F-V-Δ29TfNCS, L76V-Δ29TfNCS, MxSafC and EcMAT, the cell pellet was
resuspended in lysis buffer (100 mM HEPES, 20 mM imidazole, 100 mM NaCl, pH
7.5, and 15% v/v culture volume) with a small amount of DNAse1. The cells were
lysed by sonication (3 × (3 min ON, 3 min OFF)) and centrifuged (15,000 × g,
45 min, 4 °C). The resulting supernatant was removed and filtered (0.45 µm). A
5mL His-trap HP column was equilibrated with lysis buffer and the lysate loaded
onto the column at 1 mLmin−1. The column was washed with lysis buffer to
remove any unbound protein (six column volumes), followed by washings with a
stepwise gradient of increasing imidazole concentrations by combining lysis buffer
and elution buffer (100 mM HEPES, 500 mM imidazole, 100 mM NaCl, pH 7.5).
The column was washed with 8% elution buffer for six column volumes, 16%
elution buffer for six column volumes followed by 100% elution buffer. All
washings were performed at a flow rate of 1 mLmin−1. Fractions were analysed by
SDS–PAGE (Supplementary Figs. 1, 4–6) and fractions containing pure protein
were combined and dialysed into 20 mM Tris, 50 mM NaCl, pH 7.5 buffer. The
protein sample was centrifuged and concentrated to ~10 mgmL−1. Aliquots of
protein were stored at −80 °C until use for enzymatic reactions or in the case of
6His-TEV-M97V-Δ33TfNCS, taken through to the next step of purification for
removal of the hexahistidine tag.
For removal of the hexahistidine tag of 6His-TEV-M97V-Δ33TfNCS, TEV
protease was added to the pooled fractions and the sample dialysed overnight
(20 mM Tris, 50 mM NaCl, pH 7.5). The protein sample was then centrifuged
(15,000 × g, 20 min, 4 °C) and loaded onto a 5 mL His-trap HP column. The
supernatant was passed through the column. The column was then washed with
varying amounts of imidazole-containing elution buffer (20 mM Tris, 50 mM
NaCl, 500 mM imidazole, pH 7.5) mixed with the dialysis buffer. Fractions
containing M97V-Δ33TfNCS were pooled (Supplementary Fig. 2) and further
purified by gel filtration on a Superdex S75 column. Fractions within the major UV
absorbance peak were pooled (Supplementary Fig. 3), concentrated (to ~10 mgmL
−1) and stored at −80 °C.
Protein crystallisation. NCS protein crystals were prepared by the sitting-drop
method in 25% w/v PEG 1500, 20% glycerol. M97V-Δ33TfNCS (12.6 mgmL−1 in
20 mM Tris, 50 mM NaCl) was prepared in a 95:5 ratio with the mimic 6 (at
200 mM in DMSO), resulting in final mimic concentration of 10 mM. Crystals
were grown for 8 weeks at 20 °C then cryo-protected in the crystallisation condition
containing 10 mM mimic. Diffraction data were collected at Diamond beamline
i04. The images for both datasets were integrated using the XDS Dials software
programme. Refinement of both datasets was performed using an apo dataset of
Δ33TfNCS (WT) in the same space group (P3221) as the search model in Phaser48.
Model building of both the protein and the ligand was performed using COOT49
with refinement performed, using REFMAC5 using TLS refinement50. Figures were
prepared using USCF Chimera51. Data collection and refinement statistics are
given in Supplementary Table 1.
Analytical RP-HPLC analysis. Analysis of samples was performed using an Agi-
lent 1260 Infinity liquid chromatography system comprising of a G1329B auto-
sampler, G1311C quaternary pump, 1260 G1316A column oven and 1260 G1314F
variable wavelength detector. The system was equipped with a HiChrom ACE C18
column (250 mm × 4.6 mm). Achiral HPLC method 1: acetonitrile (MeCN) in
water (0.1% v/v TFA) was used as the mobile phase. The gradient used was: 10%
MeCN for 1 min, a linear gradient to 70% MeCN over 5 min, 100% MeCN for 30 s,
followed by 10% MeCN for 3.5 min. A flow rate of 1 mLmin−1 was used. The
initial reaction volume was diluted to 25% reaction concentration and 10 μL of
sample was injected. UV absorbance was measured at 280 nm. Achiral HPLC
method 2: MeCN in water (0.1% v/v TFA) was used as the mobile phase. The
gradient used was: 10% MeCN for 1 min, a linear gradient to 70% MeCN over
15 min, 100% MeCN for 30 s, followed by 10% MeCN for 3.5 min. A flow rate of
1 mLmin−1 was used. The initial reaction volume was diluted to 25% reaction
concentration and 10 μL of sample was injected. UV absorbance was measured at
280 nm.
Chiral HPLC analysis. Samples were analysed using a Hewlett Packard Series 1100
liquid chromatography system consisting of a G1311A Quaternary Pump, G1313A
autosampler and G1314A variable wavelength detector (methods 2 and 3). Samples
analysed by method 1 used the same system as all achiral analytical HPLC samples.
Chiral HPLC method 1: an Agilent InfinityLab Poroshell 120 Chiral-V column
(150 mm × 4.6 mm, 2.7 mM) was used with an isocratic MeOH (0.2 wt% ammo-
nium formate) mobile phase at 1 mLmin−1. UV absorbance at 280 nm was
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Fig. 7 Achiral HPLC traces of the regioselective meta-O-methylation of two THIQ products (S)-5a and (S)-5b. a Methylation of 5a to give 7a; b
methylation of 5b to give 7b. In all cases, the methylation system generating SAM is used to avoid the addition of stoichiometric quantities of SAM and is
used with the O-methyltransferases RnCOMT andMxSafC. The methyl donor, SAM is generated in situ by the enzyme EcMAT and the reaction byproduct,
SAH is broken down by another enzyme, EcMTAN.
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measured. The column temperature used was 30 °C. Chiral HPLC method 2: a
Diacel Chiralpak® AD-H column (250 mm × 4.6 mm, 5 mM) was used with an
isocratic n-hexane:ethanol:diethylamine (80:20:0.01) mobile phase at 1 mLmin−1.
UV absorbance at 280 nm was measured. The column temperature used was 30 °C.
Chiral HPLC method 3: a Diacel Chiralpak® OD column (250 mm × 4.6 mm,
5 mM) was used with an isocratic n-hexane:isopropanol:diethylamine (90:10:0.1)
mobile phase at 1 mLmin−1. UV absorbance was measured at 280 nm. The column
temperature used was 20 °C (ref. 37). Chiral HPLC method 4: a Diacel Chiralpak®
OD column (250 mm × 4.6 mm, 5 mM) was used with an isocratic n-hexane:iso-
propanol:diethylamine (95:5:0.1) mobile phase at 1 mLmin−1. UV absorbance was
measured at 280 nm. The column temperature used was 20 °C (ref. 37).
Chiral HPLC traces are given in the Supplementary Information
(Supplementary Figs. 10–22).
Semi-preparative HPLC. Reverse-phase, semi-preparative HPLC was performed
on a Dionex 580 HPLC machine with a PDA-100 photodiode array detector, P580
pump and a model ASI-100 automated sample injector. The column used was a
Phenomenex Onyx C18 (100 × 10 mm). Water (0.1% v/v TFA) and MeCN (0.1% v/
v TFA) were used as the mobile phase, using a linear gradient of 5–95% MeCN
over 36 min. A flow rate of 2 mLmin−1 was used with detection at 254 nm.
Preparative HPLC. Purification was performed using Agilent 1200 Infinity series
liquid chromatography system equipped with G1361A prep pump, G2260A
autosampler, G1364A fraction collector and G7165 multiple wavelength detector.
A Supelco Discovery®BIO Wide Pore C18-10 column (25 cm × 21.2 mm, 10 μM)
using MeCN and water as the mobile phase (both solvents contained 0.1% v/v
TFA) as the mobile phase. UV absorbance was measured at 280 nm. Preparative
HPLC method 1: 20-min gradient 25–95% MeCN (0.1% v/v TFA) in water (0.1% v/
v TFA). Preparative HPLC method 2: 20-min gradient 35–80% MeCN (0.1% v/v
TFA) in water (0.1% v/v TFA). Preparative HPLC method 3: 30-min gradient
5–95% MeCN (0.1% v/v TFA) in water (0.1% v/v TFA).
Chemical reagents. All reagents were obtained from commercial sources (Sigma
Aldrich, Fisher, Alfa Aesar) and used as received. Silica column chromatography
was performed using Geduran® Si 60 Silica (43–60 μM). Thin layer chromato-
graphy was performed using plates with a silica gel matrix on an aluminium
support. Ultraviolet light (254 nm) and ninhydrin stain was used to visualize the
plates.
Chemical analytics. 1H and 13C NMR spectra were obtained using a Bruker
Advance III 700MHz spectrometers. Chemical shifts specified are relative to tri-
methylsilane (set at 0 p.p.m.) and referenced to the residual, protonated NMR
solvent. Coupling constants in 1H-NMR spectra (J) are given in Hertz (Hz), and
described as singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q)
and multiplet (m). NMR spectra for products are shown in Supplementary
Figs. 32–72. Mass spectrometry data was obtained using a Waters Aquity UPLC-
MS system (LRMS [ES+]). Infrared data were obtained using a Bruker Alpha
Platinum-ATR machine.
NCS-catalysed reactions. Enzymatic assays were performed on a 100 μL scale and
larger-scale biotransformations were performed on a 10 mL scale. A solution of
amine (final reaction concentration of 10 mM) and sodium ascorbate (final reac-
tion concentration of 10 mM) was prepared in HEPES buffer (50 mM, pH 7.5
(except Fig. 1c where pH 6 was used)). A solution of aldehyde (200 mM in MeCN)
was prepared and the two solutions mixed in a 9:1 ratio. TfNCS (at ~10 mgmL−1
in 20 mM Tris, 50 mM NaCl, pH 7.5) was added and the reactions stirred at 37 °C.
Control reactions were performed using the same conditions but the TfNCS sample
was substituted for enzyme buffer (20 mM Tris, 50 mM NaCl, pH 7.5). To quench
the reactions, different conditions were used depending on the use of the sample.
Workup method 1 (for RP-HPLC analysis): reactions were quenched by the
addition of an equal volume of MeCN. Samples were centrifuged (16,000 × g,
10 min, 4 °C), the supernatant with an equal volume of water and analysed
immediately by analytical RP-HPLC or stored at −20 °C. Workup method 2 (for
chiral HPLC analysis): the reaction was saturated by addition of NaHCO3 and an
equal volume of EtOAc to the reaction volume was added. The samples were
vortexed (30 s) and centrifuged (16,000 × g, 5 min, 4 °C). The organic layer was
removed and left to evaporate until dryness (ca. 48 h). The sample was resuspended
in 80:20:0.1 n-hexane:ethanol:diethylamine (1.5 × initial reaction volume) and
injected for HPLC analysis. Workup method 3 (for methyltransferase reactions):
reactions were quenched by the addition of an equal volume of MeCN. Samples
were centrifuged (16,000 × g, 10 min, 4 °C) and the supernatant removed and
lyophilised.
Methyltransferase reactions44. The lyophilised NCS reaction mixture (generated
using optimised reaction conditions, Fig. 4) prepared by workup method 3 was
resuspended in buffer (250 mM HEPES, 200 mM MgCl2, 2 M KCl, pH 7.5) and
water (1:4 ratio) in an equal volume to the NCS reaction sample. ATP (100 mM in
H2O, final concentration 10 mM), L-methionine (100 mM in H2O, final
concentration 10 mM), EcMAT (9 mgmL−1 purified, 0.4 mg mL−1 final con-
centration), EcMTAN (2.5 mgmL−1 purified, 0.025 mgmL−1 final concentration)
and methyltransferase (RnCOMT: 10% v/v lysate or MxSafC: 6 mgmL−1 purified,
0.6 mg mL−1 final concentration) were added. Reaction volumes were adjusted by
addition of HEPES buffer (50 mM, pH 7.5). Reactions were performed at 37 °C,
500 r.p.m. (200 μL scale) or 150 r.p.m. (10–20 mL scale) for 24 h. Products were
prepared by preparative HPLC method 2.
Calibration curves. All calibration curves used for determination of conversions to
give products are given the Supplementary Information (Supplementary Figs. 24–
26). Preparation of the calibration curves is described in the Supplementary
Methods.
Complete chemical syntheses and analyses. Complete synthetic methods,
characterisation of THIQ products and corresponding chiral HPLC data are given
in the Supplementary Information.
Data availability
Data to support this work is available from the corresponding authors upon reasonable
request. Structural data for the co-crystallised structure of M97V-Δ33TfNCS can be
found at PDB: 6Z82.
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